---
title: "TD Cowen Keeps Their Buy Rating on Soleno Therapeutics (SLNO)"
description: "Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and Gilead Sciences. According to TipRanks, Van Buren has an average return of 3.9% and a 48.86% succ"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260046030.md"
published_at: "2025-10-06T11:36:02.000Z"
---

# TD Cowen Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

> Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and Gilead Sciences. According to TipRanks, Van Buren has an average return of 3.9% and a 48.86% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Soleno Therapeutics with a $119.30 average price target, a 101.49% upside from current levels. In a report released on October 3, Piper Sandler also maintained a Buy rating on the stock with a $145.00 price target.

Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Regeneron, and Gilead Sciences. According to TipRanks, Van Buren has an average return of 3.9% and a 48.86% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Soleno Therapeutics with a $119.30 average price target, a 101.49% upside from current levels. In a report released on October 3, Piper Sandler also maintained a Buy rating on the stock with a $145.00 price target.

### Related Stocks

- [SLNO.US - Soleno Therapeutics](https://longbridge.com/en/quote/SLNO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 双威医疗保健委任六家投行担任上市承销商 \| 联合早报网 | 双威医疗保健（Sunway Healthcare）已委任六家投资银行作为首次公开售股（IPO）的承销商，计划在马来西亚上市，预计集资超过 30 亿令吉，估值将超过 150 亿令吉。承销商包括马来亚、艾芬黄氏、联昌国际、兴业、肯纳格及大马投资 | [Link](https://longbridge.com/en/news/275451558.md) |
| 在 David Einhorn 持股以及领导层变动之后，重新审视阿卡迪亚医疗保健（ACHC）的估值 | 阿卡迪亚医疗保健（Acadia Healthcare，ACHC）在大卫·艾因霍恩（David Einhorn）披露新持股后引起关注，导致交易量增加和近期领导层变动。该股票在一天内上涨了 5.54%，7 天和 30 天的回报率分别为 25.4 | [Link](https://longbridge.com/en/news/275994576.md) |
| 2025 年的就业机会在哪里？2026 年的就业机会将会在哪里？ | 在 2025 年，职位增长微乎其微，只有教育和医疗保健（增加了 697,000 个职位）以及休闲和酒店业（增加了 119,000 个职位）显示出显著增长。其他行业，包括制造业和政府部门，经历了下降。由于婴儿潮一代的退休，失业率可能不会急剧上 | [Link](https://longbridge.com/en/news/275986113.md) |
| Jefferies 重申对诺华制药（NOVN）的持有评级 | Jefferies 分析师 James Vane 对诺华制药 (NOVN) 重申了持有评级，目标价为 110.00 瑞士法郎。专注于医疗保健领域的 Vane 在他的股票推荐中平均回报率为 -1.0%，成功率为 49.13%。此外，DZ BA | [Link](https://longbridge.com/en/news/276102881.md) |
| 如何在高估值的市场中发现被忽视的投资机会 | 这篇文章讨论了在高估值市场中寻找被忽视的投资机会。它强调了市场领导地位从主要科技股转向医疗保健、能源和金融等行业的变化。小型股最近的表现超过了大型指数，令人想起过去的市场趋势。由于暂时的市场 setback，Fiserv 和 Netflix | [Link](https://longbridge.com/en/news/275921857.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.